Posted By Madilyn Moeller, Wednesday, November 5, 2025
Galderma, the world’s largest independent global dermatology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for injection into the mid-to-deep dermis (subcutaneous and/or supraperiosteal) for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.
Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also approved to treat the midface, facial folds and wrinkles (such as nasolabial folds) and back of hands. It is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types.
“This approval reinforces our commitment to advancing our Injectable Aesthetics portfolio – the broadest on the market – to meet the diverse needs of patients. By expanding how innovations like Restylane Lyft can be used, we aim to empower aesthetic practitioners to achieve their patients’ unique aesthetic goals with enhanced flexibility and precision.” Bill Andriopoulos, PhD, Vice President of Medical Affairs, Galderma U.S., said in a release.
Galderma's Restylane portfolio offers a versatile range of HA injectables, from soft and flexible to firm gel formulations, empowering practitioners to deliver personalized aesthetic outcomes. The portfolio is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide
Restylane Lyft, developed with NASHA® technology, has a firmer gel with minimal modification, closely resembling the skin’s natural HA. With its high G-prime (a measure of firmness), Restylane Lyft is specifically designed to provide structure and support, enabling it to enhance the chin for a balanced profile.
Also in the Restylane family of hyaluronic acid (HA) dermal filler products, each designed for a specific purpose, are:
The approval is based on results from a pivotal clinical trial, confirming the clinical performance and safety of Restylane Lyft for chin enhancement. The study demonstrated its safety and effectiveness in improving chin projection three months after initial injection, with improvement sustained in the majority of patients through 12 months. Additional results showed:
How long does Restylane Lyft for chin last? Global aesthetic improvement, as assessed by both patients and investigators, remained consistently high throughout the study. At Month 3, 99.1% of investigators and 94.4% of subjects reported visible improvement. These results were maintained at Month 12, with 95.5% of investigators and 89.0% of patients continuing to report positive outcomes.
How is patient satisfaction in Restylane Lyft results? At the end of the study (Month 12), a high proportion of patients agreed or strongly agreed that Restylane Lyft delivered natural-looking chin projection, improved the appearance of the lower face, and provided a smooth transition from chin to jawline, with satisfaction rates up to 86.3%.
What side effects did patients experience? Restylane Lyft was well tolerated, with no unexpected or serious adverse events related to the product reported during the study, reinforcing its favorable safety profile. The most common side effects reported in the clinical study to support approval of augmentation of the chin region included bruising, nodules, exfoliation, hemorrhage, edema, papules and redness. Patients also reported pain, tenderness, swelling, itching, and lumps/bumps.
Before treatment, your aesthetic practitioner will conduct an initial examination to go over your goals, assess your skin, and take a medical history. Because Restylane Lyft with lidocaine contains a gram-positive bacterial protein, patients with allergies to these materials should not be treated with this type of HA injectable filler. It is also not approved for patients under 21. Speak with your provider to learn whether you will be a good candidate for chin augmentation with Restylane Lyft.
U.S. med spas can begin to offer Restylane Lyft for chin retrusion in patients 21 and older, according to this newest indication from the FDA. Refer to your treatment delegation table to learn who can inject dermal filler in your state.
Importantly, this new FDA approval also means that trainers can officially teach new and established aesthetic injectors how to inject chin filler with Galderma’s trusted dermal filler products.
Galderma, in the release, said it will continue to submit regulatory applications for Restylane Lyft for use on the chin, in the hopes of bringing this expanded application to as many countries as possible.
Restylane Lyft with Lidocaine is only available through a licensed practitioner. Read the important safety information for the Restylane family of products, explore Restylane Lyft before and after pictures, and review the science at Galderma.com or restylaneusa.com.
About the Restylane portfolio
Restylane hyaluronic acid (HA) injectables are designed differently to go beyond volumizing for natural-looking results. Its HA is exceptionally pure and its innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose. Restylane’s unique technologies, NASHA HD™, NASHA and OBT™/XpresHAn™ are meaningfully designed to mimic the diverse range of facial structures and skin layers. With the highest G’ and highest flexibility, Restylane can provide structural support, natural expressions and a healthy glow. Trusted for almost three decades, its HA gels work in sync with your skin for 100% natural looking results.
About Galderma
Galderma is the worlds’ largest independent global dermatology company, present in approximately 90 countries. It delivers an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through injectable aesthetics, dermatological skincare and therapeutic dermatology. Since its foundation in 1981, Galderma has dedicated its focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because Galderma understands that the skin we are in shapes our lives, it is advancing dermatology for every skin story. For more information: www.galderma.com.
AmSpa Connect
Store
Customer Portal
Back to All News